Lonza Group AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LZAGF research report →
Companywww.lonza.com
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing.
- CEO
- Wolfgang Wienand
- IPO
- 2009
- Employees
- 17,995
- HQ
- Basel, CH
Price Chart
Valuation
- Market Cap
- $45.16B
- P/E
- 38.02
- P/S
- 5.27
- P/B
- 3.78
- EV/EBITDA
- 20.86
- Div Yield
- 1.02%
Profitability
- Gross Margin
- 34.63%
- Op Margin
- 21.01%
- Net Margin
- 13.92%
- ROE
- 10.24%
- ROIC
- 7.21%
Growth & Income
- Revenue
- $6.53B · -0.65%
- Net Income
- $949.00M · 49.21%
- EPS
- $13.55 · 51.74%
- Op Income
- $1.24B
- FCF YoY
- -51.75%
Performance & Tape
- 52W High
- $755.96
- 52W Low
- $565.14
- 50D MA
- $631.06
- 200D MA
- $673.26
- Beta
- 0.82
- Avg Volume
- 301
Get TickerSpark's AI analysis on LZAGF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LZAGF Coverage
We haven't published any research on LZAGF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LZAGF Report →